Horizon Discovery Group plc

HZD

GB00BK8FL363

Pharmaceuticals

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-.--%	+23.00%

2022	Medical Device Innovation Consortium Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics	CI
2020	Horizon Discovery : Acquisition by PerkinElmer Completes	MT

Horizon Discovery Group plc Provides Earnings Guidance for the Six Months Ended 30 June 2017

September 08, 2017 at 02:00 am EDT

Horizon Discovery Group plc expects to report FOR THE Six Months Ended 30 June 2017 revenues of £12.1 million, in line with previous guidance, representing growth of at least 20%. Reported Group gross margins are expected to expand substantially to at least 60%.

Latest news about Horizon Discovery Group plc

Medical Device Innovation Consortium Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics	22-10-19	CI
Horizon Discovery : Acquisition by PerkinElmer Completes	20-12-23	MT
PerkinElmer (UK) Holdings Ltd. completed the acquisition of Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others.	20-12-22	CI
Horizon Discovery : Takeover by PerkinElmer Gets Court Approval	20-12-22	MT
Horizon Discovery : Soars 110% on Acquisition by PerkinElmer in $366 Million Deal	20-11-02	MT
PerkinElmer (UK) Holdings Ltd. agreed to acquire Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others for approximately £290 million.	20-11-01	CI
Transcript : Horizon Discovery Group plc, H1 2020 Earnings Call, Aug 17, 2020	20-08-17
Horizon Discovery Group plc Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-17	CI
Horizon Discovery Group plc Announces the Addition of Single Cell RNAseq-Linked Pooled CRISPR Screening to Its CRISPR Screening Services Portfolio	20-08-04	CI
Horizon Discovery Group plc Licenses Chosource Platform to TrueBinding, Inc for Development and Commercialization of Multiple Biotherapeutics	20-07-29	CI
Transcript : Horizon Discovery Group plc - Analyst/Investor Day	20-07-29
Horizon Discovery Group plc Provides Group Revenue Guidance for the Six Months Ended June 30, 2020	20-07-29	CI
Horizon Discovery Group plc Introduces Cas9 and dCas9-VPR Stable Cell Lines to Simplify and Accelerate CRISPR Gene Editing Workflows	20-07-07	CI
Rentschler Biopharma Licenses Horizon Discovery's Chosource Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins	20-05-19	CI
Horizon Discovery Group plc Announces Board Changes	20-05-01	CI
Transcript : Horizon Discovery Group plc, 2019 Earnings Call, Apr 27, 2020	20-04-27
Horizon Discovery Group plc Unable to Provide Guidance for the Full Year of 2020	20-04-27	CI
Horizon Discovery Group plc Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-27	CI
Horizon Discovery Group plc's CHOSOURCE™ Platform Supports Development of Immunotherapy for Autoimmune Diseases	20-04-22	CI
Horizon Discovery Offers CHOSOURCE™ Platform For COVID-19-Related Therapeutics and Diagnostics	20-04-14	CI
Horizon Discovery Expands Cell-Based CRISPR Screening Services	20-04-03	CI
Horizon Discovery Group plc Announces Positive Early-Stage Results for Novel Micro-Rna Therapeutic for Ischemic Heart Diseases	20-03-31	CI
Horizon Discovery Group plc Provides Revenue Guidance for the Year Ended December 31, 2019 and Fiscal Year 2020	20-02-04	CI
Horizon Discovery Group plc Grants A Multi-Product Use License of Its Gs Knockout Cho K1 Cell Line to Ngm Biopharmaceuticals, Inc	20-01-21	CI
Transcript : Horizon Discovery Group plc Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-13-2020 through Jan-16-2020	20-01-15

Chart Horizon Discovery Group plc

Duration

Period

More charts

Company Profile

Horizon Discovery Group Ltd, formerly known as Horizon Discovery Group PLC, is a United Kingdom-based life science company. The Company drives the application of gene editing and gene modulation. It offers a portfolio of tools and services to help scientists understand gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
HORIZON DISCOVERY GROUP PLC	+23.00%	412M
CSL LIMITED	-2.72%	88.91B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.25B
BIOGEN INC.	-13.92%	31.99B
UCB	+50.51%	24.73B
BIOMARIN PHARMACEUTICAL INC.	-15.25%	15.54B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-39.93%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.08%	12.05B
INCYTE CORPORATION	-14.80%	12.02B
SWEDISH ORPHAN BIOVITRUM AB	+6.22%	8.84B

Biopharmaceuticals